UK markets closed

Neurocrine Biosciences, Inc. (0K6R.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
98.40+4.00 (+4.24%)
At close: 02:30PM BST

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600
https://www.neurocrine.com

Sector(s)
Industry
Full-time employees1,100

Key executives

NameTitlePayExercisedYear born
Dr. Kevin C. Gorman Ph.D.CEO & Director1.58M31.31M1958
Mr. Matthew C. AbernethyChief Financial Officer906.76kN/A1980
Dr. Jude Onyia Ph.D.Chief Scientific Officer621.66kN/A1964
Mr. Eric S. BenevichChief Commercial Officer805k295.52k1965
Dr. Eiry Wyn RobertsChief Medical Officer925.46kN/A1964
Dr. Dimitri E. GrigoriadisChief Research OfficerN/AN/A1958
Jane SorensenHead of Investor RelationsN/AN/AN/A
Mr. Darin M. LippoldtChief Legal Officer & Corp. Sec.N/AN/A1966
Mr. Kyle W. GanoChief Bus. Devel. and Strategy OfficerN/AN/A1973
Ms. Julie S. CookeChief HR OfficerN/AN/A1966
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Corporate governance

Neurocrine Biosciences, Inc.’s ISS governance QualityScore as of 1 June 2022 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.